CAE-S: CAE for Poorly Adherent Individuals With Schizophrenia
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
|Condition or Disease
Patients with schizophrenia will be randomly assigned to receive either CAE-S or eTAU following the baseline assessment. The primary feasibility outcomes will be attendance and patient satisfaction (Aim 1) and change from baseline to 12 weeks in schizophrenia symptoms as measured by the Positive and Negative Symptom Scale (PANSS) (Aim 2). An exploratory evaluation (Aim 3) will examine the posited mechanistic underpinnings of the CAE-S intervention by assessing change from screening to 12 weeks in psychotropic medication adherence as measured by the Tablets Routine Questionnaire (TRQ) and validated by eCAP (objective bottle openings). Secondary measures will include the Clinical Global Impression (CGI), functional status, quality of life and attitudes towards medication.
Arms and Interventions
|Experimental: Customized Adherence Enhancement for Schizophrenia (CAE-S)
CAE is an adjunctive (to standard medication treatment) behavioral intervention delivered virtually (real-time one on one video-conferencing) in 6 individual sessions. All participants will receive content from the 4 currently existing CAE modules delivered over a 6-session series spaced out over approximately 6-10 weeks. The material from the 4 modules will be broken down into predetermined sub-sections and delivered in 6 sessions. The modules themselves are delivered in sections (thematic units within the module) and do not correspond to a specific session. The 4 CAE modules are Psychoeducation, Communication with Providers, Medication Routines, and Substance Use.
Behavioral: Customized Adherence Enhancement for Schizophrenia (CAE-S)
6-session series spaced out over approximately 6-10 weeks
|Other: Enhanced Treatment as Usual (eTAU)
To optimize control intervention rigor, the eTAU participants will view a pre-taped series of 6 videos (based on NAMI or DBSA general wellness guidelines) 1:1 with a therapist who has similar credentials and competency as the CAE mental health clinician. The therapist will view the video with the participant and field questions the patient may have.
Other: Enhanced Treatment as Usual (eTAU)
eTAU participants will view a pre-taped series of 6 videos
Primary Outcome Measures
- Average number of CAE sessions attended by those in the CAE group after 12 weeks [12 weeks]
- Percentage of subjects in the CAE group that agree or strongly agree that the intervention was useful at 12 weeks [12 weeks]
Secondary Outcome Measures
- Change in Positive and Negative Syndrome Scale (PANSS) total score between CAE-S and eTAU groups at 12 weeks [12 weeks]
The PANSS is a clinician rated scale used for measuring symptom severity of patients with schizophrenia. Total scores range from 30 to 210, with higher scores indicating more severe schizophrenia
- Change in Tablets Routine Questionnaire (TRQ) at 12 weeks [12 weeks]
The TRQ is a validated self-report measure that identifies proportion of days with missed doses in the past 7 days (past-week) and in the past 30 days (past-month). Lower scores (a smaller proportion/percentage n of missed medication) represent better adherence, while higher scores (a larger proportion/percentage of missed medication) represent worse adherence.
- Change in eCAP use at 12 weeks [12 weeks]
Study participants will be given an eCAP device for one of their pill bottles, which will record time/date of bottle opening. eCAP will be used to monitor the antipsychotic dosed most often (index drug). If more than one drug is dosed at the same frequency, the antipsychotic most recently added to the regimen will be the index drug.. We will calculate a percent of doses taken by dividing the number of times the bottle is opened by the number of times it should have been opened as per the prescription.
Individuals age 18 and older with schizophrenia as confirmed by the Mini International Psychiatric Inventory (MINI)
Prescribed an antipsychotic medication for treatment of schizophrenia
Known to have medication treatment adherence problems as identified by the Tablets Routine Questionnaire (TRQ, 20% or more missed medications in past week or past month)
Ability to be rated on psychiatric rating scales
Currently in treatment or scheduled to receive treatment at a Community Mental Health Clinic (CMHC) or other clinical setting able to provide mental health care during and after study participation
Able to provide written, informed consent to study participation
Has access to electronic device and internet to complete sessions conducted on videoconferencing platform
Prior or current treatment with clozapine (clozapine therapy includes additional medication-related monitoring and clinical visits that may impact medication adherence)
Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial
Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist
Immediate risk of harm to self or others
Female who is currently pregnant or breastfeeding
Does not have access to electronic device and internet to complete sessions conducted on videoconferencing platform
Contacts and Locations
|University Hospitals Cleveland Medical Center
Sponsors and Collaborators
- Martha Sajatovic
- Merck Sharp & Dohme LLC
- Principal Investigator: Martha Sajatovic, MD, University Hospitals Cleveland Medical Center
Study Documents (Full-Text)None provided.